Unclear or conflicting scientific evidence
- L-carnitine
: The human body produces L-carnitine in the liver, kidney, and brain. Early evidence suggests that oral supplements of L-carnitine may help treat Peyronie's disease. However, additional research is needed before a firm conclusion can be made.
- Avoid if allergic to L-carnitine. Use cautiously with peripheral vascular disease, high blood pressure, alcohol-induced liver cirrhosis, or diabetes. Use cautiously in low birth weight infants and individuals on hemodialysis. Use cautiously if taking anticoagulants (blood thinners), beta-blockers, or calcium channel blockers. Avoid if pregnant or breastfeeding.
- Para-aminobenzoic acid (PABA)
: Para-aminobenzoic acid (PABA) is a naturally occurring non-protein amino acid. Several studies suggest that PABA supplements may help reduce symptoms of Peyronie's disease. However, a firm conclusion cannot be made until additional studies are performed.
- Avoid if allergic to PABA or its derivatives. Avoid if taking sulfonamides. Use cautiously with kidney disease, diabetes, low blood sugar levels, bleeding disorders, or if taking blood thinners. Stop taking PABA if rash, nausea, or decreased appetite occurs. Avoid oral use in children and pregnant or breastfeeding women. Other forms of PABA are not recommended if pregnant or breastfeeding, due to a lack of safety data. It is recommended that individuals have their liver function and blood sugar levels monitored while taking PABA.